XNCR
Xencor Inc
Key Financials
Revenue
$125.6M
↑ 13.7%
Net Income
$-91923000
↑ 60.5%
Operating Income
$-177502000
↑ 0.5%
Total Assets
$875.5M
↓ 8.0%
Total Liabilities
$239.9M
↓ 13.7%
EPS (Diluted)
$-1.24
↑ 65.4%
Cash & Equivalents
$54.1M
↑ 32.3%
Shareholders' Equity
$635.6M
↓ 6.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| ARS | 4/27/2026 | View on SEC |
| DEFA14A | 4/27/2026 | View on SEC |
| DEF 14A | 4/27/2026 | View on SEC |
| 8-K | 4/27/2026 | View on SEC |
| 4 | 4/13/2026 | View on SEC |
| 144 | 4/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | XNCR |
| Company Name | Xencor Inc |
| CIK | 1326732 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 626-305-5900 |